-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Leriglitazone Hydrochloride in Friedreich Ataxia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Leriglitazone Hydrochloride in Friedreich Ataxia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leriglitazone Hydrochloride in Friedreich Ataxia Drug Details: Leriglitazone hydrochloride is under...
-
Company Insights
Innovation and Patenting activity of AMN Healthcare Services Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of AMN Healthcare Services Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBT-101 in Adrenomyeloneuropathy (AMN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBT-101 in Adrenomyeloneuropathy (AMN) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBT-101 in Adrenomyeloneuropathy (AMN) Drug Details: SBT-101 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VK-0214 in Adrenomyeloneuropathy (AMN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VK-0214 in Adrenomyeloneuropathy (AMN) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VK-0214 in Adrenomyeloneuropathy (AMN)Drug Details: VK-0214 (formerly MB-10866) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leriglitazone Hydrochloride in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Leriglitazone Hydrochloride in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Drug Details: Leriglitazone hydrochloride is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXL-770 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PXL-770 in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Drug Details: PXL-770 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Endometrial Cancer Drug Details: Tremelimumab (Imjudo) is a human monoclonal monospecific antibody against...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXL-770 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXL-770 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PXL-770 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:PXL-770 is under development for the treatment...